Overview
bluebird bio develops gene therapies using lentiviral vectors to treat severe genetic diseases like thalassemia and sickle cell. Tailored for modern biology and life science teams.
Key Highlights
- FDA-approved ZYNTEGLO and SKYSONA lentiviral gene therapy products.
- Pipeline spanning sickle cell, beta-thalassemia, and oncology.
- Manufacturing expertise in autologous cell therapy workflows.
Ideal For
- Clinicians evaluating approved gene therapies
- Payers and policymakers monitoring outcomes and access
- Patients seeking advanced treatments for genetic disorders
Quick Links
- Official site: bluebirdbio.com
- Add to BioDir collections to track updates and collaborators.